Abstract 17773: Baseline Cardiovascular Disease, Risk Factors, and Subsequent Changes Among Newly Diagnosed Prostate Cancer Patients

Background: Currently there are 3 million prostate cancer (PCa) survivors in the US with roughly 500,000 receiving androgen-deprivation therapy (ADT), a mainstay of treatment. As cancer survival continues to improve, focus shifts to treatment-related morbidity and non-cancer mortality of which cardiovascular disease (CVD) is most common. Although an FDA safety label was added to ADT in 2010 recommending management of traditional cardiovascular (CV) risk factors due to a possible increase in CVD and diabetes, little is known regarding baseline and subsequent changes in all newly diagnosed prostate cancer patients. Methods: The Synthetic Derivative at Vanderbilt University Medical Center, a database of over 2.5 million de-identified patient records, was used to identify prevalence of baseline CVD (CAD, heart failure, stroke) and CV risk factors (hypertension, dyslipidemia, diabetes mellitus, body mass index (BMI), smoking status), and linked to the Vanderbilt Tumor Registry to identify all newly diagnosed p...